N,N-diallyltryptamine | 60676-77-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: N,N-diallyltryptamine
• 英文别名: N-allyl-N-[2-(1H-indol-3-yl)ethyl]prop-2-en-1-amine；DALT；diallyl-(2-indol-3-yl-ethyl)-amine；Diallyl-(2-indol-3-yl-aethyl)-amin；N-[2-(1H-indol-3-yl)ethyl]-N-prop-2-enylprop-2-en-1-amine
• CAS: 60676-77-9
• 化学式: C₁₆H₂₀N₂
• 分子量: 240.348
• InChiKey: LQEATNFJCMVKAC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  19
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N,N-diallyltryptamine 在 Wilkinson's catalyst 作用下， 以 甲苯 为溶剂， 反应 5.0h， 以71%的产率得到2-allyl-1-ethyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
  参考文献：
  名称：

  通过N-烯丙基丙胺的异构化合成四氢β-咔啉：以Pictet-Spengler为主题的金属催化变体。

  摘要：

  提出了一种有效且广泛适用的四氢-β-咔啉的经典Pictet-Spengler合成方法。该方法依赖于烯丙基胺的金属催化异构化以形成反应性亚胺中间体，该中间体可以被束缚的吲哚亲核试剂捕获。

  DOI：

  10.1039/c2cc17704h
• 作为产物：
  描述：

  吲哚-3-乙醛酰氯 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 150.0 ℃ 、1.93 MPa 条件下， 反应 4.08h， 生成 N,N-diallyltryptamine
  参考文献：
  名称：

  Receptor binding profiles and quantitative structure–affinity relationships of some 5-substituted- N , N -diallyltryptamines

  摘要：

  N,N-Diallyltryptamine (DALT) and 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT) are two tryptamines synthesized and tested by Alexander Shulgin. In self-experiments, 5-MeO-DALT was reported to be psychoactive in the 12-20 mg range, while the unsubstituted compound DALT had few discernible effects in the 42-80 mg range. Recently, 5-MeO-DALT has been used in nonmedical settings for its psychoactive effects, but these effects have been poorly characterized and little is known of its pharmacological properties. We extended the work of Shulgin by synthesizing additional 5-substituted-DALTs. We then compared them to DALT and 5-MeO-DALT for their binding affinities at 45 cloned receptors and transporter proteins. Based on in vitro binding affinity, we identified 27 potential receptor targets for the 5-substituted- DALT compounds. Five of the DALT compounds had affinity in the 10-80 nM range for serotonin 5-HT1A and 5-HT2B receptors, while the affinity of DALT itself at 5-HT1A receptors was slightly lower at 100 nM. Among the 5-HT2 subtypes, the weakest affinity was at 5-HT2A receptors, spanning 250-730 nM. Five of the DALT compounds had affinity in the 50-400 nM range for serotonin 5-HT1D, 5-HT6, and 5-HT7 receptors; again, it was the unsubstituted DALT that had the weakest affinity at all three subtypes. The test drugs had even weaker affinity for 5-HT1B, 5-HT1E, and 5-HT5A subtypes and little or no affinity for the 5-HT3 subtype. These compounds also had generally nanomolar affinities for adrenergic alpha(2A), alpha(2B), and alpha(2C) receptors, sigma receptors sigma(1) and sigma(2), histamine H-1 receptors, and norepinephrine and serotonin uptake transporters. They also bound to other targets in the nanomolar-to-low micromolar range. Based on these binding results, it is likely that multiple serotonin receptors, as well as several non-serotonergic sites are important for the psychoactive effects of DALT drugs. To learn whether any quantitative structure-affinity relationships existed, we evaluated correlations among physicochemical properties of the congeneric 5-substituted-DALT compounds. The descriptors included electronic (sigma(p)), hydrophobic (pi), and steric (CMR) parameters. The binding affinity at 5-HT1A, 5-HT1D, 5-HT7, and kappa opioid receptors was positively correlated with the steric volume parameter CMR. At alpha(2A), alpha(2B), and alpha(2C) receptors, and at the histamine H-1 receptor, binding affinity was correlated with the Hammett substituent parameter sigma(p); higher affinity was associated with larger sigma(p) values. At the sigma(2) receptor, higher affinity was correlated with increasing p. These correlations should aid in the development of more potent and selective drugs within this family of compounds. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.12.053

文献信息

• General Strategy for the Syntheses of Corynanthe, Tacaman, and Oxindole Alkaloids
  作者：Alexander Deiters、Martin Pettersson、Stephen F. Martin

  DOI：10.1021/jo061032t

  日期：2006.8.1

  We report herein the total synthesis of the corynanthe alkaloid dihydrocorynantheol and the formal syntheses of the indole alkaloids tacamonine, rhynchophylline, and hirsutine. The strategies for assembling the corynanthe and tacaman skeletal frameworks comprised of both the classical ABD → ABCD and ABC → ABCD approaches wherein the variously substituted piperidinone D-rings were formed via ring-closing

  我们在此报告了七氢萘生物碱二氢七氢萘酚的总合成以及吲哚生物碱他卡莫宁，乙酰胆碱和hirsutine的形式合成。由经典的ABD→ABCD和ABC→ABCD方法组成的corynanthe和tacaman骨架骨架的组装策略，其中各种取代的哌啶酮D环是通过闭环复分解（RCM）形成，然后加成1,4-在C（15）处引入必要的侧链。由于向α，β-不饱和内酰胺中添加1,4-代表了一个不发达的领域，我们对两种不饱和内酰胺进行了一系列研究，采用有机铜酸盐和金属烯醇盐作为亲核试剂。这些研究表明，源自格氏试剂的有机铜和化学计量的CuCN或催化量的CuBr·DMS络合物都是极好的亲核试剂。TMSC1是优化这些反应的关键添加剂。在这些1,4-加成中，衍生自1,3-二硫杂环戊基-2-羧酸乙酯的阴离子也是极好的亲核试剂，尽管将此类1,4-加成的立体化学反应衍生自咔啉衍生的不饱和内酰胺。吲哚氮原子。这些生物碱的ABD→AB
• Design and synthesis of β-carboline and combretastatin derivatives as anti-neutrophilic inflammatory agents
  作者：Sunil Kumar、Yi-Hsuan Wang、Po-Jen Chen、Yu-Chia Chang、Hemant K. Kashyap、Ya-Ching Shen、Huang-Ping Yu、Tsong-Long Hwang

  DOI：10.1016/j.bioorg.2021.104846

  日期：2021.6

  A series of β-carboline derivatives was synthesized by the Pictet-Spengler reaction with or without the combretastatin skeleton. The structures of these derivatives were elucidated by spectroscopic techniques. All synthesized compounds were evaluated for their anti-inflammatory activity in human neutrophils. Among them, two compounds, NTU-228 and HK-72, showed significant inhibitory effects on N-formyl-Met-Leu-Phe

  通过Pictet-Spengler反应合成了一系列β-咔啉衍生物，有或没有combretastatin骨架。这些衍生物的结构通过光谱技术阐明。评估了所有合成化合物在人中性粒细胞中的抗炎活性。其中，两种化合物 NTU-228 和 HK-72 对N-甲酰基-Met-Leu-Phe (fMLF) 诱导的人中性粒细胞超氧阴离子生成显示出显着抑制作用，IC 50值为 5.58 ± 0.56 和 2.81 ±分别为 0.07 μM。NTU-228 和 HK-72 都不会对人中性粒细胞造成细胞毒性。NTU-228 抑制 p38 和 JNK 丝裂原活化蛋白激酶 (MAPK) 的磷酸化和细胞内 Ca 2+水平（[Ca 2+] i ) 在 fMLF 激活的人类中性粒细胞中。此外，HK-72在人中性粒细胞中选择性抑制 fMLF 诱导的 p38 和 [Ca 2+ ] i磷酸化。分子对接分析显示 HK-72 对 p38
• [EN] COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS<br/>[FR] FORMULATIONS SALINES DE COMPOSÉS PHARMACEUTIQUES À BASE D'AGENTS COMPLEXANTS
  申请人：BEXSON BIOMEDICAL INC

  公开号：WO2022109050A1

  公开（公告）日：2022-05-27

  Provided herein are pharmaceutical formulations and pharmaceutical compound salts which utilize complexing agents as counterions. Such formulations and salts are useful for treating a variety of disease and disorders.

  本文提供了药物制剂和药物化合物盐，其使用络合剂作为反离子。这些制剂和盐对治疗各种疾病和障碍有用。
• Complexing agent salt formulations of pharmaceutical compounds
  申请人：Bexson Biomedical, Inc.

  公开号：US11534454B2

  公开（公告）日：2022-12-27

  Provided herein are pharmaceutical formulations and pharmaceutical compound salts which utilize complexing agents as counterions. Such formulations and salts are useful for treating a variety of disease and disorders.

  本文提供了利用络合剂作为反离子的药物制剂和药物化合物盐。这些制剂和盐类可用于治疗各种疾病和失调。
• Vitali; Mossini, Bollettino Scientifico della Facolta di Chimica Industriale di Bologna, 1959, vol. 17, p. 84,86
  作者：Vitali、Mossini

  DOI：——

  日期：——